Characteristics of HCV Resistance in an International Cohort After a Decade of Direct-Acting Antivirals

Direct-acting antiviral (DAA) regimens provide a cure in >95% of patients with chronic HCV infection. However, in some patients in whom therapy fails, resistance-associated substitutions (RASs) can develop, limiting retreatment options and risking onward resistant virus transmission.

A study, published in JHEP Reports, evaluated RAS prevalence and distribution, including novel NS5A RASs and clinical factors associated with RAS selection, among patients who experienced DAA treatment failure.

Full study results can be accessed here.